Ranibizumab Treatment for Age-Related Macular Degeneretion

The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02158624

Acronym

QUATRO

Enrollment

100

Registered

2014-06-09

Start date

2013-12-31

Completion date

2015-12-31

Last updated

2014-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Disorder Due to Age-related Macula Degeneration

Brief summary

To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

Interventions

DRUGIntravitreal Lucentis 0.5mg

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD * Subjects of either gender age 50 years or older * Visual acuity better than 0.05 decimal( 20/400 Snellen) * Signed informed consent form

Exclusion criteria

* Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy * Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye * Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye * Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye * Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors * The pregnant or lactating woman

Design outcomes

Primary

Measure	Time frame	Description
Baseline change of visual acuity and QOL after ranibizumab treatment	3 months	Analyze the correlation between visual acuity improvement and QOL assessment using VFQ-25 and Patient Satisfaction Questionnaire before and after initial ranibizumab treatment for AMD patients.

Secondary

Measure	Time frame
To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations	1year

Other

Measure	Time frame
Baseline change of central retinal thickness by OCT examination.	3 months, 1 year

Countries

Japan

Contacts

Primary ContactTatsuro Ishibashi, MD. PhD

ishi@eye.med.kyushu-u.ac.jp+81-92-642-5648

Backup ContactYuji Oshima, MD. PhD

yuji@eye.med.kyushu-u.ac.jp+81-92-642-5648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026